State Street’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,907,317
| Closed | -$112M | – | 4688 |
|
|
2023
Q2 | $112M | Buy |
2,907,317
+219,269
| +8% | +$5.63M | 0.01% | 1137 |
|
|
2023
Q1 | $62.2M | Buy |
2,688,048
+29,092
| +1% | +$693K | ﹤0.01% | 1496 |
|
|
2022
Q4 | $69.7M | Buy |
2,658,956
+193,237
| +8% | +$4.28M | ﹤0.01% | 1414 |
|
|
2022
Q3 | $48.5M | Buy |
2,465,719
+912,778
| +59% | +$18.3M | ﹤0.01% | 1615 |
|
|
2022
Q2 | $27.2M | Sell |
1,552,941
-44,061
| -3% | -$692K | ﹤0.01% | 2029 |
|
|
2022
Q1 | $26.1M | Buy |
1,597,002
+309,362
| +24% | +$4.21M | ﹤0.01% | 2198 |
|
|
2021
Q4 | $21M | Sell |
1,287,640
-110,529
| -8% | -$1.57M | ﹤0.01% | 2447 |
|
|
2021
Q3 | $17.8M | Buy |
1,398,169
+458,063
| +49% | +$6.03M | ﹤0.01% | 2554 |
|
|
2021
Q2 | $13.3M | Buy |
940,106
+675,206
| +255% | +$10.8M | ﹤0.01% | 2747 |
|
|
2021
Q1 | $4.12M | Sell |
264,900
-21,557
| -8% | -$352K | ﹤0.01% | 3134 |
|
|
2020
Q4 | $4.54M | Buy |
286,457
+17,490
| +7% | +$264K | ﹤0.01% | 3008 |
|
|
2020
Q3 | $3.27M | Buy |
268,967
+5,807
| +2% | +$77.8K | ﹤0.01% | 2999 |
|
|
2020
Q2 | $3.04M | Buy |
263,160
+24,207
| +10% | +$334K | ﹤0.01% | 3005 |
|
|
2020
Q1 | $3.27M | Sell |
238,953
-1,035
| -0.4% | -$12.2K | ﹤0.01% | 2831 |
|
|
2019
Q4 | $1.42M | Sell |
239,988
-17,590
| -7% | -$95.6K | ﹤0.01% | 3346 |
|
|
2019
Q3 | $1.36M | Buy |
257,578
+11,060
| +4% | +$73.4K | ﹤0.01% | 3338 |
|
|
2019
Q2 | $1.9M | Buy |
246,518
+25,324
| +11% | +$386K | ﹤0.01% | 3259 |
|
|
2019
Q1 | $4.4M | Sell |
221,194
-715
| -0.3% | -$12.5K | ﹤0.01% | 2809 |
|
|
2018
Q4 | $2.93M | Buy |
221,909
+1,803
| +0.8% | +$36K | ﹤0.01% | 2964 |
|
|
2018
Q3 | $8.09M | Buy |
220,106
+8,668
| +4% | +$278K | ﹤0.01% | 2643 |
|
|
2018
Q2 | $7.4M | Buy |
211,438
+56,996
| +37% | +$2.19M | ﹤0.01% | 2675 |
|
|
2018
Q1 | $7.18M | Sell |
154,442
-196,192
| -56% | -$7.18M | ﹤0.01% | 2618 |
|
|
2017
Q4 | $13.2M | Buy |
350,634
+64,302
| +22% | +$2.81M | ﹤0.01% | 2321 |
|
|
2017
Q3 | $15.2M | Buy |
286,332
+149,392
| +109% | +$8.88M | ﹤0.01% | 2207 |
|
|
2017
Q2 | $7.81M | Buy |
136,940
+10,520
| +8% | +$528K | ﹤0.01% | 2516 |
|
|
2017
Q1 | $6.79M | Buy |
126,420
+11,659
| +10% | +$659K | ﹤0.01% | 2553 |
|
|
2016
Q4 | $6.54M | Buy |
114,761
+1,520
| +1% | +$92K | ﹤0.01% | 2534 |
|
|
2016
Q3 | $7.04M | Buy |
113,241
+4,538
| +4% | +$321K | ﹤0.01% | 2375 |
|
|
2016
Q2 | $6.15M | Buy |
108,703
+76,531
| +238% | +$4.65M | ﹤0.01% | 2482 |
|
|
2016
Q1 | $2.06M | Buy |
32,172
+7,990
| +33% | +$646K | ﹤0.01% | 2995 |
|
|
2015
Q4 | $3.4M | Buy |
24,182
+5,925
| +32% | +$805K | ﹤0.01% | 2750 |
|
|
2015
Q3 | $1.77M | Buy |
18,257
+3,820
| +26% | +$455K | ﹤0.01% | 3042 |
|
|
2015
Q2 | $2.19M | Buy |
+14,437
| New | +$2.38M | ﹤0.01% | 3039 |
|
State Street's KDNY Position: Q3 2023 in Review
State Street sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 2,907,317 shares — an estimated $112M sold.
State Street first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $112M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- State Street reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- State Street sold 2,907,317 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $112M.
- State Street first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- State Street's Chinook Therapeutics, Inc. Common Stock position peaked at $112M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.